評論
打印
本期內容：
Eli Lilly said that a clinical trial for a new drug to slow the onset of Alzheimer’s had failed. The drug, solanezumab, was tested on patients with mild cases of Alzheimer’s, who showed only a slight improvement after 18 months of treatment. The experiment had been closely watched by medical researchers and hopes were high that solanezumab would be the first drug approved to treat the disease.
Clinical trial: 臨床試驗
Onset：開始
Alzheimer‘s： 老年癡呆癥
想了解更多信息，請關注:
新浪微博：教書匠小夏
微信公眾號：教書匠小夏
